Published in J Clin Invest on December 22, 2008
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Inflammation in neurodegenerative diseases. Immunology (2010) 3.22
T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature (2017) 2.70
Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis (2009) 2.49
Trafficking of immune cells in the central nervous system. J Clin Invest (2010) 2.17
T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol (2009) 1.78
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol (2012) 1.78
Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm (Vienna) (2010) 1.66
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol (2015) 1.66
CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol (2009) 1.43
Microglia development and function. Annu Rev Immunol (2014) 1.41
The immunology of neurodegeneration. J Clin Invest (2012) 1.41
Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm (2014) 1.35
Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm (Vienna) (2011) 1.35
Integrating pathways of Parkinson's disease in a molecular interaction map. Mol Neurobiol (2013) 1.34
Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One (2010) 1.29
Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol (2009) 1.27
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci (2009) 1.27
Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) (2009) 1.27
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21
MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci (2013) 1.21
Targeting neural precursors in the adult brain rescues injured dopamine neurons. Proc Natl Acad Sci U S A (2009) 1.21
Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol (2009) 1.20
The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem (2009) 1.20
Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One (2011) 1.15
The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease. J Neurosci (2012) 1.14
Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med (2010) 1.13
Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. J Proteome Res (2009) 1.13
Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm (2013) 1.12
Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol (2012) 1.11
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics (2012) 1.11
Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol (2012) 1.10
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis (2013) 1.08
MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun (2014) 1.07
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol (2011) 1.06
Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro (2013) 1.05
Inflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link? Mol Neurobiol (2012) 1.04
The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 1.03
The dopaminergic system in autoimmune diseases. Front Immunol (2014) 1.02
The executioners sing a new song: killer caspases activate microglia. Cell Death Differ (2011) 1.02
IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis (2011) 1.00
Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 1.00
Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol Neurodegener (2010) 1.00
Mechanisms of altered redox regulation in neurodegenerative diseases--focus on S--glutathionylation. Antioxid Redox Signal (2012) 1.00
Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. Acta Neuropathol (2014) 1.00
Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One (2012) 0.99
Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain. Pharmacogenomics J (2009) 0.98
Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener (2015) 0.98
Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. Neurotoxicology (2009) 0.98
Markov Chain Ontology Analysis (MCOA). BMC Bioinformatics (2012) 0.97
CD 4+ T cells in the pathobiology of neurodegenerative disorders. J Neuroimmunol (2009) 0.97
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol (2015) 0.97
Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson's Disease-like Dementia. Cell (2015) 0.96
Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. PLoS One (2011) 0.96
Innate inflammation in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 0.96
Neuronal MHC-I expression and its implications in synaptic function, axonal regeneration and Parkinson's and other brain diseases. Front Neuroanat (2014) 0.96
Parkinson's disease and systemic inflammation. Parkinsons Dis (2011) 0.96
Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease. Parkinsons Dis (2010) 0.95
Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep (2013) 0.94
Immunolocalization of influenza A virus and markers of inflammation in the human Parkinson's disease brain. PLoS One (2011) 0.93
A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum Mol Genet (2012) 0.93
The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. J Neuroinflammation (2012) 0.93
Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis (2015) 0.93
Immune aging, dysmetabolism, and inflammation in neurological diseases. Front Neurosci (2015) 0.92
CD4+ T cells mediate cytotoxicity in neurodegenerative diseases. J Clin Invest (2009) 0.92
T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation (2014) 0.91
MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediators Inflamm (2013) 0.91
The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. Immunology (2014) 0.91
Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. Parkinsons Dis (2011) 0.91
FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice. Acta Neurochir Suppl (2011) 0.91
Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front Mol Neurosci (2011) 0.90
Protective role of Fas-FasL signaling in lethal infection with herpes simplex virus type 2 in mice. J Virol (2009) 0.90
Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder. Int J Tryptophan Res (2010) 0.90
The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis (2011) 0.89
Evidence of inflammatory system involvement in Parkinson's disease. Biomed Res Int (2014) 0.89
Parkinson's disease and immune system: is the culprit LRRKing in the periphery? J Neuroinflammation (2012) 0.88
Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clin Geriatr Med (2010) 0.88
Chronic consumption of a western diet induces robust glial activation in aging mice and in a mouse model of Alzheimer's disease. Sci Rep (2016) 0.87
Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease. Sci Rep (2016) 0.87
GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol (2013) 0.87
Axonal damage in multiple sclerosis. Mt Sinai J Med (2011) 0.87
Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Transl Neurodegener (2014) 0.86
Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease. PLoS One (2015) 0.86
microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. J Neurosci (2016) 0.86
Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm (Vienna) (2011) 0.86
Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One (2010) 0.86
Immune responses in Parkinson's disease: interplay between central and peripheral immune systems. Biomed Res Int (2014) 0.86
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? Parkinsons Dis (2011) 0.85
Aspects of innate immunity and Parkinson's disease. Front Pharmacol (2012) 0.85
Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J Mol Cell Biol (2014) 0.85
Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol Commun (2015) 0.85
Striatal blood-brain barrier permeability in Parkinson's disease. J Cereb Blood Flow Metab (2015) 0.84
Infiltration of circulating myeloid cells through CD95L contributes to neurodegeneration in mice. J Exp Med (2015) 0.84
The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. J Neuroinflammation (2011) 0.84
Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother (2011) 0.84
Effects of inflammation on stem cells: together they strive? EMBO Rep (2015) 0.84
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 27.85
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature (1992) 7.66
Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol (2005) 7.47
Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell (1994) 7.23
CD4 T cells: fates, functions, and faults. Blood (2008) 7.03
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med (2007) 6.19
Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature (1991) 5.98
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med (1999) 4.88
CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell (1991) 4.05
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol (2005) 3.58
STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A (2003) 3.46
CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A (2008) 2.72
Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 2.71
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol (1988) 2.28
Understanding cell death in Parkinson's disease. Ann Neurol (1998) 2.16
Neuroinflammatory processes in Parkinson's disease. Ann Neurol (2003) 2.10
Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci U S A (1994) 2.09
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.05
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm (Vienna) (2006) 1.96
Evidence that a significant number of naive T cells enter non-lymphoid organs as part of a normal migratory pathway. Eur J Immunol (2006) 1.87
Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl (2000) 1.83
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol (2007) 1.80
Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. J Neurosci (1999) 1.70
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol (1999) 1.59
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci (1999) 1.58
Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol (2003) 1.57
Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci (2007) 1.55
Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology (2007) 1.52
Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem (2006) 1.49
Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol (2002) 1.45
Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev (2004) 1.42
Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Proc Natl Acad Sci U S A (1995) 1.40
Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem (2004) 1.38
Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord (2005) 1.36
TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis (2007) 1.35
Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol (2003) 1.33
The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration (1996) 1.20
Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol (2005) 1.16
Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci (2004) 1.13
Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol (2000) 1.05
Assessing fetal nerve cell grafts in Parkinson's disease. Nat Med (2008) 1.04
Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monit (2002) 1.03
Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp Neurol (2002) 0.99
Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease. J Exp Med (2005) 0.93
Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Neuropathol Appl Neurobiol (2000) 0.91
Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta Neurobiol Exp (Wars) (2003) 0.91
Integrity of the blood-cerebrospinal fluid barrier in early Parkinson's disease. Neurosci Lett (2001) 0.88
Effects of MPTP on the cerebrovasculature. Int J Dev Neurosci (1991) 0.80
Reduced susceptibility to kainic acid-induced excitoxicity in T-cell deficient CD4/CD8(-/-) and middle-aged C57BL/6 mice. J Neuroimmunol (2004) 0.79
Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science (2005) 11.31
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74
Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity (2006) 10.58
NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell (2011) 9.75
Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol (2006) 9.53
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature (2008) 9.16
Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A (2004) 9.00
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
MAP kinases in the immune response. Annu Rev Immunol (2001) 7.62
Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med (2004) 7.49
Interchromosomal associations between alternatively expressed loci. Nature (2005) 7.45
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
IRAK-M is a negative regulator of Toll-like receptor signaling. Cell (2002) 6.79
T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity (2007) 6.61
Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature (2007) 6.58
Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science (2006) 6.55
A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 6.20
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A (2005) 5.96
RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature (2002) 5.95
Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity (2006) 5.91
Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity (2007) 5.73
The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A (2008) 5.59
Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell (2004) 5.50
Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature (2005) 5.32
A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol (2009) 5.26
A toll-like receptor that prevents infection by uropathogenic bacteria. Science (2004) 5.26
Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. Science (2009) 5.24
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest (2009) 5.09
Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med (2007) 4.95
Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A (2004) 4.88
Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 4.88
TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science (2005) 4.86
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med (2005) 4.85
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection. Nat Immunol (2006) 4.70
Long-range intrachromosomal interactions in the T helper type 2 cytokine locus. Nat Immunol (2004) 4.67
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity (2008) 4.67
TGF-beta: a master of all T cell trades. Cell (2008) 4.60
Transforming growth factor-beta in T-cell biology. Nat Rev Immunol (2002) 4.50
Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med (2007) 4.47
Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol (2006) 4.44
T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med (2005) 4.28
Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med (2006) 4.28
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 4.23
Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol (2003) 4.15
The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature (2002) 4.15
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity (2007) 4.07
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity (2006) 4.02
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02
Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A (2009) 3.99
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J Exp Med (2006) 3.76
Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A (2006) 3.74
The inflammasome: first line of the immune response to cell stress. Cell (2006) 3.73
Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC. Cell Host Microbe (2007) 3.52
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet (2003) 3.51
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A (2003) 3.46
Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med (2005) 3.43
ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med (2008) 3.39
Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity (2011) 3.38
OspC facilitates Borrelia burgdorferi invasion of Ixodes scapularis salivary glands. J Clin Invest (2004) 3.38
Mechanism of p38 MAP kinase activation in vivo. Genes Dev (2003) 3.36
T helper cell differentiation: regulation by cis elements and epigenetics. Immunity (2006) 3.33
Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32
Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity (2008) 3.26
TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A (2004) 3.26
Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol (2010) 3.25
Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity (2007) 3.19
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med (2008) 3.15
JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science (2012) 3.12
The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol (2002) 3.08
Cutting edge: changes in histone acetylation at the IL-4 and IFN-gamma loci accompany Th1/Th2 differentiation. J Immunol (2002) 3.04
Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol (2005) 2.96
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A (2003) 2.94
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Regulation of the Th2 cytokine locus by a locus control region. Immunity (2003) 2.84
Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med (2004) 2.84
A Yersinia effector protein promotes virulence by preventing inflammasome recognition of the type III secretion system. Cell Host Microbe (2010) 2.84
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
An essential role of the Forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. Immunity (2009) 2.82
Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med (2002) 2.77
miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science (2010) 2.75
Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria. Proc Natl Acad Sci U S A (2006) 2.75
Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol (2005) 2.75
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol (2009) 2.73
Does Toll-like receptor 3 play a biological role in virus infections? Virology (2004) 2.73
Caspase activity mediates the differentiation of embryonic stem cells. Cell Stem Cell (2008) 2.68
Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity (2009) 2.66